New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

That’s where anti-inflammatory therapeutics come into play, offering hope for millions of people living with chronic inflammation. The global anti-inflammatory therapeutics market size was $98,026 ...